masthead-publications

Categories

Filter by Topics

ABC-DLBCL ADCC Gene Alteration Adenocarcinoma airway remodeling AKT Targeted Therapy ALK Alleles Anti-TNF Alpha Therapy Anus AR-Specific T Cells Asthma asthma auto-immune disorder Autocrine Signaling AXL B-cell lines B-cell lymphoma biofluid Biology of neoplasia biomarker Biomarker Biomarker Analysis Biomarker Discovery biomarker patient stratification Biomarker Validation Biomarkers biomarkers Biomarkers Outcome Bladder bladder cancer Brain Brain RNA Breast Breast Cancer cancer immune response Carcinoma CD-19 CD44 CDKN2A mutation Cell line Cells Cerebral Spinal Fluid checkpoint inhibitor Checkpoint Inhibitors chemoresistance chronic obstructive pulmonary disease Circulating miRNAs Classification Clinical Outcome Prediction clinical trial Clinical Trials cMET Colon Colon cancer Colorectal cancer comparative approach Comparison study comprehensive gene expression study Cord blood buffy coat Core Needle Biopsy Custom mRNA Cyclin E mRNA Cytokines detection Developmental Immunotherapy Diabetes Diagnostic Biomarkers differential diagnosis Differential Expression differentiation Diffuse large B-cell lymphoma Diffuse Large B-cell Lymphoma Dissecting Genomic Biomarkers DLBCL DLBDL Drug Response drug safety Drug Targets Efficacy EGFR Muatations EMT EMT signals Encephalophy epidemiology outcomes Epigenetics Epigenomic Epstein-Barr ERBB2 Esophageal cancer Exosomes Expression Profiling Expression profiling Extracted RNA Fabry Disease Feasibility FFPE FFPE canine tumor FGF Ligand Trap FGFR Gastrointestinal Cancers gene expression Gene expression Gene Expression Analysis Gene Expression Comparisons Gene expression profiling Gene Expression Signatures Gene Fusions Gene pathway analysis Gene Signatures Genetic polymorphism Genomic Genomic bioinformatics Head and Neck Cancer Heart HER2 histone deacetylase inhibitors HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBLCL Cell of Origin Assay HTG EdgeSeq DLBLCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel human Human serum hypoxia Immune Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune-checkpoint blockade immune-related colitis Immuno-Oncology immunofluorescence immunology Immunotherapy immunotherapy induction chemotherapy Inflammation Inflammatory signatures Interferon Gamma Signature invasive breast carcinoma juvenile arthritis Kidney Liposarcoma liquid biopsy Liver Lung Lung adenocarcinoma Lung cancer lymph node metastasis Lymphoma Melanoma mesothelioma MET Metastatic colon cancer metastatic colorectal Metastatic prostate cancer Methods Comparison mice Mice PDX microRNA miRNA miRNA WTA miRQC study Molecular Characterization Mouse Mouse mRNA mRNA mRNA custom mRNA expression in tumors mTOR pathway mTORC1 mTORC2 mucin hypersecretion Multiple myeloma Muscle mutation Mutations MYC myocardial reperfusion Myocarditis NAFLD Nash and Fibrosis Natural killer cells Neoantigens neuroendocrine tumor nivolumab non-Hodgkin Lymphoma non-small cell lung cancer Non-small cell lung cancer Novel Therapeutic Targets NSCLC NTRK1 Oesophageal Adenocarcinoma Oncogenes Oncology Oncology-Biomarker Onomirs Oral oral cancer oral squamous cell carcinoma osteoclast Ovarian cancer Overexpression P13KmTOR Inhibitor palbociclib Pancreas pancreatic ductal Pancreatic ductal adenocarcinoma Paralysis Parkinson's Disease partition approach pathology Pathway Analysis Pathways PCA Cell Lines PD-1 Pd-L1 PD-L1 Phase 3 clinical trial PI3K signaling pathway PIK3CA mutation Plasma plasma Platform Comparison pralatrexate predictive predictive biomarker Predictive Biomarkers Predictive Modeling pro-inflammatory cytokines profiling Profiling Signature Development Prognostic prognostic Prognostic Biomarkers Programmed cell death protein 1 Programmed death ligand 1 programmed death-1 programmed death-ligand 1 progression free-survival Prostate prostate cancer qNPA qPCR Radioimmunotherapy Rearrangements rectum regulation renal disease Responders vs Non-responders Response rate RET Reveal Rheumatoid Arthritis risk score ROS1 safety SCBC SCLC Serum serum Signaling Inhibitors Signaling Pathways Signature Development Signature Pathway Analysis Signature Validation Signatures sinonasal undifferentiated carcinoma Skin Small bowel Small cell bladder cancer Small Cell Bladder Cancer Small cell lung cancer SPECS Lung Consortium Squamous cell carcinoma Sub-typing surveillance Survival Outcomes Survival plots synovial fluid System Validation T cell T-cells Technology Comparison therapeutic target Therapeutic targets Tissue-based biomarkers TMB Toxicity TP53 mutation Transplantation Treatment Outcome treatment stratification Treatment Targets Triple Negative Breast Cancer Tumor biology tumor heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment tumor mutational burden type 1 diabetes Urothelial carcinoma Uveal melanoma VEGFR venetoclas Vistusertib WNT Path Signaling Xenograft Tissue

2020

Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.

Naseem, M., et al. Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial. Poster session presented at Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 245)

View External Link

CCR5 Δ32 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials.

Lenz, A., et al. CCR5 Δ32 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials.  Poster session presented at 2020 Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 170)

View External Link

Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.

Battaglin, F., et al. Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. Poster session  Clin Oncol 38, 2020 (suppl 4; abstr 190) presented at 2020 Gastrointestinal Cancers Symposium; 2020 Jan 25; San Francisco, CA.

View External Link

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Woment with Treatment-Naïve Metastatic Breast Cancer

Finn, R. S., et al. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Woment with Treatment-Naïve Metastatic Breast Cancer. Clinical Cancer Research | Precision Medicine and Imaging. 2020 Jan 15. 26:110-21. DOI: 10.1158/1078-0432.CCR-19-0751.

Download pdf 1.4MB

MicroRNA-based risk scoring system to identify early-stage oral squamous cell carcinoma patients at high-risk for cancer-specific mortality

Yoon, A. J., et al. MicroRNA-based risk scoring system to identify early-stage oral squamous cell carcinoma patients at thigh-risk for cancer-specific mortality. Head and Neck. 2020; 1-14

Download pdf 1.7MB

2019

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Younes, A., et al. Journal of Clinical Oncology 2019 Mar22;37(15):1285-1295. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Download pdf 1.2MB

Page last updated February 21, 2020